<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052645</url>
  </required_header>
  <id_info>
    <org_study_id>20-010454</org_study_id>
    <nct_id>NCT05052645</nct_id>
  </id_info>
  <brief_title>Ear Acupuncture for Neuropathic Pain</brief_title>
  <official_title>Auricular Acupuncture in the Treatment of Neuropathic Pain: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information on the effectiveness of auricular&#xD;
      acupuncture (i.e., the placement of acupuncture needles in specific points on the ear) in&#xD;
      reducing pain and improving quality of life among patients experiencing neuropathic pain in&#xD;
      the acute inpatient rehabilitation setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in self-reported neuropathic pain scores</measure>
    <time_frame>Daily during inpatient stay, approximately 7-10 days</time_frame>
    <description>Measured on the numeric rating scale for pain (NRS Pain) for pain intensity using a scale of 0=no pain, 10=worst imaginable</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive standard of care neuropathic pain treatment without acupuncture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acupuncture Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive acupuncture treatment in addition to to the standard of care neuropathic pain treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Auricular acupuncture</intervention_name>
    <description>Placement of acupuncture needles in specific points on the ear in two consecutive treatments spaced 7 days apart.</description>
    <arm_group_label>Acupuncture Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have acute or chronic neuropathic pain of any etiology (traumatic,&#xD;
             non-traumatic, central, peripheral, and mixed cases).&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Ability to speak English and complete all aspects of this trial.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Patients will have stable neuropathic pain medication dosing for 3 days prior to&#xD;
             enrollment to include gabapentin, pre-gabalin, TCAs, duloxetine, carbamazepine,&#xD;
             oxcarbazepine, and venlafaxine).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with platelet count &lt;50,000 or known bleeding disorder.&#xD;
&#xD;
          -  Patients in a severe immunocompromised state.&#xD;
&#xD;
          -  Pregnant women. All patients who meet the criteria will have their medical records&#xD;
             reviewed to ensure they are not pregnant.&#xD;
&#xD;
          -  Allergy to gold.&#xD;
&#xD;
          -  Use of non-FDA approved herbal supplements. Their effect on enhancing or blunting&#xD;
             effect of acupuncture is not known. Patients using medical marijuana with an approved&#xD;
             prescription from a state issuing such prescriptions will not be excluded.&#xD;
&#xD;
          -  Current infection of the skin or cartilage of the ear.&#xD;
&#xD;
          -  Patients already using adjuvant modalities such as chiropractic, massage, yoga, tai&#xD;
             chi, massage will not be excluded, but those who add in these modalities during the&#xD;
             course of the intervention and observation period will be excluded.&#xD;
&#xD;
          -  Patients not anticipated to stay for a minimum of 7 days after enrollment.&#xD;
&#xD;
          -  Patient without mental capacity to participate in the consent process and the&#xD;
             questionnaire responses.&#xD;
&#xD;
          -  Fear of needles or no interest in acupuncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Chon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Tony Y. Chon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

